Trial
NCT02767934
Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
University of Washington
Collaborators
National Cancer Institute (NCI)
Condition
B Acute Lymphoblastic Leukemia
Intervention
Laboratory Biomarker Analysis
Why stopped
Terminated due to lack of efficacy
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-08-20